Assembly Bio reports positive Phase 1a safety, target engagement data for ABI-6250 NTCP inhibitor
Bitget2026/10/05 14:03Assembly Biosciences set two AASLD Liver Meeting 2026 poster presentations for ABI-6250 Phase 1a data on November 7, 2026. Early-stage results showed the oral NTCP inhibitor was well tolerated in healthy participants with no serious adverse events reported. Pharmacodynamic findings indicated target engagement, supporting plans to move ABI-6250 into Phase 2 development. Phase 2 start is slated for Q4 2026 in chronic hepatitis delta virus infection. A separate Phase 2 program in cholestatic liver diseases is planned for Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051000PRIMZONEFULLFEED9839048) on October 05, 2026, and is solely responsible for the information contained therein.
- Assembly Biosciences set two AASLD Liver Meeting 2026 poster presentations for ABI-6250 Phase 1a data on November 7, 2026.
- Early-stage results showed the oral NTCP inhibitor was well tolerated in healthy participants with no serious adverse events reported.
- Pharmacodynamic findings indicated target engagement, supporting plans to move ABI-6250 into Phase 2 development.
- Phase 2 start is slated for Q4 2026 in chronic hepatitis delta virus infection.
- A separate Phase 2 program in cholestatic liver diseases is planned for Q1 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
About 700,000 BTC have flowed out of exchanges in the past year.
Korean retail investors shift to the US in Q3: Sold over 5.5 trillion won of Korean stocks, purchased more than 10 trillion won of US stocks
In the third quarter, Korean retail investors made net purchases of US stocks worth approximately 10.15 trillion won, marking a complete reversal from the previous pattern in the first half of the year, when they made net purchases of nearly 100 trillion won in KOSPI stocks. In September alone, the sell-off amount reached as high as 14.2 trillion won. Analysts attribute this shift to a combination of factors: a sharp decline in KOSPI at high levels, the continued strength of the US stock market driven by AI themes, and the appreciation of the Korean won reducing currency exchange costs.
Copper prices approach historic highs! UBS remains bullish: "Still most optimistic"
Crypto prices
More
